Pharmaceutical Company Adapts Sales Strategy Post-Mergers

This case study details how a United States-based pharmaceutical company restructured itself following a series of mergers and acquisitions, focusing on respiratory diseases and central nervous system disorders. The company faced significant challenges in its sales operations due to the need to redesign incentive compensation programs to align with the strategies of the newly acquired businesses. Issues arose from expanded data sets and data integrity problems, leading to errors in sales commission payments and a lack of accessible information for sales executives. To address these challenges, the company implemented the Optymyze unified, no-code platform for sales performance management, which facilitated the redesign of their sales commission system. The outcomes included improved integration of sales operations, enhanced data controls, new quota-setting methodologies, and insightful performance analytics. This adaptation allowed the company to increase its salesforce and manage complex commission plans without additional administrative resources.